[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
…, ME Deming, LA Jackson, AR Branche… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
[HTML][HTML] Baricitinib plus remdesivir for hospitalized adults with Covid-19
…, DA Sweeney, HM El Sahly, AR Branche… - … England Journal of …, 2021 - Mass Medical Soc
Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …
[HTML][HTML] Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo …
…, AR Falsey, EE Walsh, AR Branche… - The lancet respiratory …, 2021 - thelancet.com
Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …
[HTML][HTML] Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
…, K Reinhart, AR Falsey, A Branche… - The Lancet infectious …, 2018 - thelancet.com
Background In February, 2017, the US Food and Drug Administration approved the blood
infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory …
infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory …
[PDF][PDF] Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
…, AW Dretler, DL de Castilla, AR Branche… - The lancet respiratory …, 2022 - thelancet.com
Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis
M Savic, Y Penders, T Shi, A Branche… - Influenza and other …, 2023 - Wiley Online Library
Background Respiratory syncytial virus (RSV)‐associated acute respiratory infection (ARI)
is an underrecognized cause of illness in older adults. We conducted a systematic literature …
is an underrecognized cause of illness in older adults. We conducted a systematic literature …
S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit
…, P Kanagaiah, FA Chaves, H Yang, AR Branche… - MBio, 2020 - Am Soc Microbiol
The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of …
infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of …
[HTML][HTML] Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
AR Branche, NG Rouphael, DJ Diemert, AR Falsey… - Nature medicine, 2023 - nature.com
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
[HTML][HTML] Parainfluenza virus infection
AR Branche, AR Falsey - Seminars in respiratory and critical …, 2016 - thieme-connect.com
Human parainfluenza viruses (HPIVs) are single-stranded, enveloped RNA viruses of the
Paramyoviridaie family. There are four serotypes which cause respiratory illnesses in children …
Paramyoviridaie family. There are four serotypes which cause respiratory illnesses in children …
